Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | NXP800 |
| Synonyms | |
| Therapy Description |
NXP800 is an inhibitor of the HSF1 pathway, with potential antitumor activity (PMID: 37017629). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| NXP800 | NXP-800|NXP 800|CCT361814|CCT-361814|CCT 361814 | NXP800 is an inhibitor of the HSF1 pathway, with potential antitumor activity (PMID: 37017629). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05226507 | Phase I | NXP800 | A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers | Active, not recruiting | USA | GBR | 0 |
| NCT06420349 | Phase I | NXP800 | NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma | Active, not recruiting | USA | 0 |